Analysis by Kaplan–Meier survival curves of ADAM17 immunostaining at first showed that low ADAM17 H score associated with better survival in ovarian cancer patients undergoing first-line treatment plus bevacizumab, suggesting that association of ADAM17 inhibition with this therapeutic schedule might improve efficacy. The gene discussed is ADAM17; the disease is ovarian cancer.